Meronem (Meropenem)

What Is Meronem and What Is It Used For?

Quick Answer: Meronem (meropenem) is a carbapenem-class antibiotic that kills bacteria by disrupting their cell wall synthesis. It is administered intravenously and is used for serious infections including pneumonia, meningitis, complicated abdominal infections, and febrile neutropenia.

Meronem belongs to the carbapenem group of antibiotics, which are among the most potent beta-lactam antibiotics available in modern medicine. Carbapenems occupy a critical position in the antimicrobial armamentarium because of their exceptionally broad spectrum of activity and their stability against most beta-lactamase enzymes that commonly render other antibiotics ineffective. Meropenem, the active ingredient in Meronem, was first approved for medical use in the 1990s and has since become a cornerstone in the treatment of severe hospital-acquired infections worldwide.

The mechanism of action of meropenem involves binding to penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cells. By inhibiting these essential enzymes, meropenem prevents the final cross-linking step in bacterial cell wall synthesis, causing the cell wall to weaken and the bacterium to undergo lysis (cell death). This bactericidal action means meropenem actively kills bacteria rather than merely inhibiting their growth, making it particularly effective in patients with compromised immune systems who cannot rely solely on their own defences to clear an infection.

Meropenem demonstrates activity against an impressively broad range of pathogens. It is effective against gram-positive organisms such as Streptococcus pneumoniae and Staphylococcus aureus (methicillin-sensitive strains), gram-negative organisms including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae, as well as anaerobic bacteria such as Bacteroides fragilis. This broad coverage makes it invaluable when the causative pathogen has not yet been identified or when polymicrobial infections are suspected.

Approved Indications

Meronem is approved for use in adults and children aged 3 months and older for the treatment of the following conditions:

• Hospital-acquired pneumonia (including ventilator-associated pneumonia) – a serious lung infection that develops during hospitalisation
• Pulmonary infections in cystic fibrosis – recurrent and often resistant lung infections in patients with this genetic condition
• Complicated urinary tract infections – kidney infections (pyelonephritis) and other UTIs that have not responded to first-line treatment
• Complicated intra-abdominal infections – such as peritonitis, abscesses, and post-surgical infections within the abdomen
• Intrapartum and postpartum infections – serious infections occurring during or after childbirth, including endometritis and wound infections
• Complicated skin and soft tissue infections – deep tissue infections, necrotising fasciitis, and severe wound infections
• Acute bacterial meningitis – a life-threatening infection of the membranes surrounding the brain and spinal cord
• Febrile neutropenia – fever in patients with dangerously low white blood cell counts, typically following chemotherapy
• Bacteraemia (bloodstream infection) – when associated with or suspected to be secondary to any of the above infections

What Should You Know Before Taking Meronem?

Quick Answer: Do not use Meronem if you are allergic to meropenem or other carbapenems. Use with caution if you have a history of penicillin or cephalosporin allergy, liver or kidney disease, or seizure disorders. Meropenem must not be used concurrently with valproic acid.

Before starting treatment with meropenem, it is essential that your healthcare provider has a complete picture of your medical history, current medications, and any known allergies. This information helps ensure that meropenem is both safe and appropriate for your specific situation. Because meropenem is typically administered in hospital settings or under close medical supervision, your treating physician will conduct a thorough assessment before initiating therapy.

Contraindications

Meropenem must not be used in the following circumstances:

• Known hypersensitivity to meropenem – if you have ever had an allergic reaction to meropenem or any of the excipients in the formulation (including anhydrous sodium carbonate)
• Severe allergy to other carbapenems – such as imipenem, ertapenem, or doripenem, as cross-reactivity between carbapenems is common
• Severe allergy to other beta-lactams – patients with a confirmed severe (anaphylactic) reaction to penicillins or cephalosporins may also react to meropenem, although the cross-reactivity rate is estimated to be low (approximately 1–3%)

Warnings and Precautions

Inform your doctor before receiving meropenem if any of the following apply to you:

• Liver disease: Meropenem is partly metabolised in the liver. Patients with hepatic impairment should be monitored with regular liver function tests during treatment. Signs of liver problems include yellowing of the skin or eyes (jaundice), itchy skin, dark urine, or pale stools.
• Kidney disease: Approximately 70% of meropenem is excreted unchanged by the kidneys. Dose reduction is necessary in patients with creatinine clearance below 51 mL/min. Your doctor will calculate the appropriate dose based on your renal function.
• Seizure history or CNS disorders: Although meropenem has a lower seizure potential compared to imipenem, seizures have been reported, particularly in patients with pre-existing CNS conditions, renal impairment, or when higher-than-recommended doses are used.
• Previous antibiotic-associated diarrhoea: If you have experienced severe diarrhoea with previous antibiotic use, you may be at increased risk of Clostridioides difficile infection (CDI), a potentially serious bowel condition.

During treatment, your doctor may monitor for signs of serious skin reactions. Although rare, meropenem has been associated with severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome). If you develop a widespread rash with blistering, peeling, or mucosal involvement, treatment should be stopped immediately.

Unexplained muscle pain, tenderness, or weakness accompanied by dark urine may indicate rhabdomyolysis (muscle breakdown), which can lead to kidney damage. Contact your doctor immediately if these symptoms occur.

Pregnancy and Breastfeeding

The safety of meropenem during pregnancy has not been established through controlled clinical trials in humans. Animal reproductive studies have not demonstrated direct harmful effects on foetal development; however, these findings cannot always be directly extrapolated to humans. Meropenem should preferably be avoided during pregnancy unless the treating physician determines that the potential benefit to the mother clearly justifies the potential risk to the foetus. In practice, meropenem may be used in pregnant women with life-threatening infections where no safer alternative exists.

Small amounts of meropenem are excreted in breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue meropenem therapy, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother. If meropenem is deemed essential, temporary cessation of breastfeeding during treatment and for a short period afterwards may be recommended.

Driving and Operating Machinery

No formal studies on the effects of meropenem on driving ability have been conducted. However, meropenem has been associated with headache, dizziness, and paraesthesia (tingling sensations), all of which could impair your ability to drive or operate machinery safely. In rare cases, meropenem can cause seizures accompanied by loss of consciousness. You should not drive or operate heavy machinery if you experience any of these side effects. Assess your own condition before undertaking activities that require alertness.

How Does Meronem Interact with Other Drugs?

Quick Answer: The most critical interaction is with valproic acid/sodium valproate, where meropenem can reduce anticonvulsant levels by 60–100%, risking seizures. Probenecid increases meropenem exposure and should be avoided. Oral anticoagulants may have enhanced effects when co-administered with meropenem.

Drug interactions are an important consideration whenever a new medication is introduced, and meropenem is no exception. Although meropenem has fewer clinically significant interactions than many other antibiotics (owing to minimal hepatic metabolism and no interaction with the cytochrome P450 enzyme system), several interactions are critically important and can have life-threatening consequences if overlooked.

Major Interactions

The mechanism behind the meropenem–valproic acid interaction is not fully understood but appears to involve increased renal clearance and inhibition of the enzymatic hydrolysis of valproic acid glucuronide back to valproic acid. Multiple case reports and pharmacokinetic studies have confirmed that this interaction is both rapid in onset and clinically devastating, with breakthrough seizures occurring in patients whose epilepsy was previously well controlled.

Other Notable Interactions

It is important to inform your healthcare team about all medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. Although meropenem does not interact with the cytochrome P450 enzyme system (which is responsible for many drug-drug interactions), the interactions described above can have serious clinical consequences and should never be overlooked.

What Is the Correct Dosage of Meronem?

Quick Answer: The typical adult dose of meropenem is 500 mg to 2 g given intravenously every 8 hours, depending on the type and severity of infection. Children receive 10–40 mg/kg every 8 hours. Doses must be reduced in patients with impaired kidney function.

Meropenem dosing is determined by the type, location, and severity of the infection being treated. The drug is always administered intravenously – either as a bolus injection over approximately 5 minutes or as an infusion over 15 to 30 minutes – because it is not absorbed when taken orally. Your doctor will determine the most appropriate dose, route, and duration of treatment based on your individual clinical situation.

Adults

The duration of treatment varies by indication but typically ranges from 5 to 14 days. For bacterial meningitis, treatment is usually continued for at least 10 to 14 days. For febrile neutropenia, therapy may continue until the neutrophil count recovers to a safe level. Extended infusions (over 3–4 hours) are increasingly used in some centres to optimise the pharmacokinetic/pharmacodynamic profile, particularly against organisms with higher minimum inhibitory concentrations (MICs).

Children (3 months to 17 years)

Dose Adjustment in Kidney Impairment

Because meropenem is primarily eliminated by the kidneys, dose adjustment is essential in patients with reduced renal function. Your doctor will calculate the appropriate dose based on your creatinine clearance (CrCl):

Patients undergoing haemodialysis should receive their dose after the dialysis session, as meropenem is removed by dialysis. Continuous renal replacement therapy (CRRT) also affects meropenem clearance, and specialised dosing is required in intensive care settings.

Missed Dose

If a dose of meropenem is missed, it should be administered as soon as possible. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. A double dose should never be given to make up for a missed one. Maintaining consistent dosing intervals is important to keep meropenem blood levels within the therapeutic range and to maximise antibacterial efficacy.

Overdose

In the event of accidental overdose, contact your doctor or go to the nearest hospital emergency department immediately. Symptoms of meropenem overdose may include nausea, vomiting, and diarrhoea. In severe cases, seizures may occur. There is no specific antidote for meropenem; treatment is supportive. Haemodialysis can remove meropenem from the blood and may be considered in cases of significant overdose, particularly in patients with renal impairment.

What Are the Side Effects of Meronem?

Quick Answer: Common side effects include diarrhoea, nausea, vomiting, headache, rash, and injection site reactions. Uncommon effects include blood count changes, fungal infections, and low potassium. Rare but serious reactions include seizures, severe skin reactions, and anaphylaxis.

Like all antibiotics, meropenem can cause side effects, although not everyone who receives it will experience them. Most side effects are mild and resolve once treatment is completed. However, some reactions can be serious and require immediate medical attention. The frequency categories below follow the standard classification used by the European Medicines Agency (EMA).

Additional serious reactions that have been reported with unknown frequency include:

• Severe skin reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome. These present as widespread, painful rashes with blistering, peeling skin, fever, and mucosal involvement. Seek emergency medical care immediately.
• Haemolytic anaemia: Destruction of red blood cells, which may cause unexpected breathlessness or dark/red-brown urine. A positive Coombs test may be detected during treatment.
• Rhabdomyolysis: Muscle breakdown causing unexplained muscle pain, tenderness, weakness, and dark urine. Can lead to acute kidney injury.
• Hepatotoxicity: Liver injury presenting as jaundice (yellow skin and eyes), itching, dark urine, and pale stools. Liver function should be monitored during prolonged treatment.
• Agranulocytosis: Severe reduction in white blood cells, increasing susceptibility to serious infections. Symptoms include persistent high fever and sore throat.

If you notice any side effects not listed here, or if any of the side effects become severe, inform your healthcare provider. Reporting suspected adverse reactions after authorisation of the medicinal product is important for ongoing safety monitoring.

How Should You Store Meronem?

Quick Answer: Store unopened vials at or below 30°C. Once reconstituted, use immediately or within strict time limits: up to 3 hours at room temperature or up to 12–24 hours refrigerated, depending on the diluent used. Do not freeze reconstituted solutions.

Proper storage of meropenem is essential to ensure the drug remains effective and safe for use. The stability of reconstituted meropenem solutions is limited, and strict adherence to storage guidelines is particularly important for patients receiving home IV antibiotic therapy (OPAT – Outpatient Parenteral Antimicrobial Therapy).

Unopened Vials

• Store at or below 30°C
• Keep in the original packaging to protect from light
• Do not use after the expiry date printed on the packaging
• Keep out of the sight and reach of children

Reconstituted Solutions for IV Injection

• Use immediately after preparation
• Maximum storage: 3 hours at room temperature (up to 25°C) from the start of reconstitution to the end of injection
• Maximum storage: 12 hours if refrigerated (2–8°C)

Reconstituted Solutions for IV Infusion

• If dissolved in sodium chloride 0.9%: use within 3 hours at room temperature or 24 hours if refrigerated
• If dissolved in glucose (dextrose) 5%: use immediately – do not store
• From a microbiological perspective, the product should be used immediately unless the preparation method excludes any risk of microbial contamination

Unused or expired medication should not be disposed of via household waste or the sewage system. Return it to your pharmacy for safe disposal in accordance with local regulations, to help protect the environment.

What Does Meronem Contain?

Quick Answer: Meronem contains the active substance meropenem (as meropenem trihydrate) and one excipient: anhydrous sodium carbonate. It is a white to pale yellow powder supplied in glass vials.

Understanding the composition of a medication is important for patients with known sensitivities or dietary restrictions. Meronem has a simple formulation with minimal excipients.

Active Substance

• Meronem 500 mg: Each vial contains meropenem trihydrate equivalent to 500 mg of anhydrous meropenem
• Meronem 1 g: Each vial contains meropenem trihydrate equivalent to 1 g of anhydrous meropenem

Excipient

• Anhydrous sodium carbonate – used as a buffering agent to adjust the pH of the reconstituted solution. This is the source of the sodium content (45 mg per 500 mg vial; 90 mg per 1 g vial)

Appearance and Packaging

Meronem is supplied as a white to pale yellow powder for injection or infusion in single-use glass vials. It is available in packs of 1 or 10 vials. Before administration, the powder must be reconstituted with a suitable diluent (water for injections for IV bolus; sodium chloride 0.9% or glucose 5% for IV infusion).

The marketing authorisation for Meronem is held by Pfizer. The product is manufactured at Pfizer facilities in Zaventem, Belgium. Generic versions of meropenem are available from multiple manufacturers worldwide, all containing the same active substance and requiring the same standards of bioequivalence.

How Can You Help Prevent Antibiotic Resistance?

Quick Answer: Always complete the full prescribed course of meropenem. Never use antibiotics that were not prescribed for you. Do not share antibiotics with others. These simple steps help prevent the development of antibiotic-resistant bacteria.

Antibiotic resistance is one of the most pressing global health threats of the 21st century, and carbapenem-resistant organisms represent a particularly dangerous category. According to the World Health Organization, antimicrobial resistance (AMR) caused an estimated 1.27 million deaths globally in 2019, and this number is projected to rise significantly without concerted action. The emergence of carbapenem-resistant Enterobacterales (CRE) has been described by public health agencies as a “nightmare bacteria” scenario, because these organisms are resistant to nearly all available antibiotics.

Meropenem occupies a critical position as one of the last-line treatments for multidrug-resistant gram-negative infections. When bacteria develop resistance to carbapenems, treatment options become extremely limited, often requiring toxic reserve antibiotics such as colistin or complex combination regimens. For this reason, the responsible use of meropenem – both at the individual patient level and at the health system level – is of paramount importance.

You can help preserve the effectiveness of antibiotics like meropenem by following these principles:

• Complete the full course: Take your antibiotic exactly as prescribed, for the full duration recommended by your doctor. Do not stop early because you feel better, as this allows partially resistant bacteria to survive and multiply.
• Never self-medicate with antibiotics: Only use antibiotics that have been specifically prescribed for you by a qualified healthcare professional for your current infection.
• Do not share antibiotics: Antibiotics prescribed for one person may not be appropriate for another, even if the symptoms appear similar.
• Do not keep leftover antibiotics: Return any unused medication to your pharmacy for safe disposal.
• Practice good hygiene: Hand washing and infection prevention measures reduce the need for antibiotic treatment in the first place.

Frequently Asked Questions About Meronem